Premium
The Epstein–Barr virus nuclear antigen‐1 may act as a transforming suppressor of the HER2 / neu oncogene
Author(s) -
Chuang Tzu-Chao,
Way Tzong-Der,
Lin Yen-Shing,
Lee Ying-Chu,
Law Sai-Lung,
Kao Ming-Ching
Publication year - 2002
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(02)03658-x
Subject(s) - oncogene , transfection , her2/neu , recombinant dna , biology , suppressor , cancer research , virus , viral oncogene , microbiology and biotechnology , epstein–barr virus , virology , antigen , cancer , cell culture , gene , immunology , genetics , breast cancer , cell cycle
It is known that the HER2 / neu proto‐oncogene is associated with a wide variety of human cancers and considered to be an attractive target for developing anti‐cancer agents. We report here for the first time that the Epstein–Barr virus nuclear antigen‐1 (EBNA1) suppresses the HER2 / neu oncogene expression at the transcriptional level. Recombinant clones of EBNA1 were subcloned and stably transfected into HER2 / neu ‐overexpressing human ovarian cancer SKOV3.ip1 cells. These EBNA1‐containing clones down‐regulated the endogenous production of p185 HER2 / neu . In addition, the EBNA1‐expressing stable transfectants showed reduced growth rate, low soft agarose colony‐forming ability and tumorigenic potential as compared with the parental line. These data suggest that EBNA1 may act as a transforming suppressor of the HER2 / neu oncogene.